Hungarian National Systemic Amyloidosis Registry
Official title: Hungarian National Systemic Amyloidosis Registry (AMYREG) - A Multi-Center, Longitudinal, Observational Survey of Patients With Systemic Amyloidosis
Run by Semmelweis University · NCT07689331 · Data updated 2026-11-12
This registry collects medical data from adults with systemic amyloidosis across Hungary to help understand how the disease is diagnosed and treated in real-world practice.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | Semmelweis University Academic / other |
| Locations | 12 sites (Balatonfüred and 11 other locations) |
| Status | Recruiting |
| Started | March 8, 2026 |
| Main results expected | May 2028 |
| Study ends | May 2028 |
| Registry record updated | July 8, 2026 |
| Trial ID | NCT07689331 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18 years) diagnosed with systemic amyloidosis who are treated in participating Hungarian centers and provide informed consent.
✕Probably not a fit
Patients without confirmed systemic amyloidosis or those who do not consent may not contribute data or benefit from the registry.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a multicenter registry in Hungary that retrospectively and prospectively collects data on adults with systemic amyloidosis, including ATTR, AL, and related cardiomyopathy, from inpatient and outpatient departments. The study design is observational and non-interventional, with data aimed at describing diagnostic patterns, treatments, and outcomes across multiple specialties. Enrollment requires confirmed diagnosis, informed consent, physician consent, and available medical history, with data entered from participating centers nationwide. The registry was established in 2025 to centralize information and improve understanding of disease burden and care practices.
Why it matters
Potential benefit: If successful, the registry could improve understanding of how systemic amyloidosis is diagnosed and managed in real-world settings and inform future care strategies.
How similar studies have gone: Registries and observational cohorts in systemic amyloidosis have helped characterize practice patterns and outcomes in real-world settings.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of systemic amyloidosis * Patients aged ≥18 years at the time of enrollment * Signed informed consent form by the patient * Treating physician's consent * Availability of accessible medical history Exclusion Criteria: * Lack of informed consent in the prospective study
Where it's running
-
Balatonfüredi Állami Szívkórház
Balatonfüred, Hungary Recruiting -
Budapesti Szent Margit Kórház
Budapest, Hungary Recruiting -
Budapesti Péterfy Sándor utcai Kórház - Rendelőintézet
Budapest, Hungary Recruiting -
Department of Internal Medicine and Hematology, Semmelweis University
Budapest, Hungary Recruiting -
Gottsegen National Cardiovascular Center
Budapest, Hungary Recruiting -
Dél-pesti Centrumkórház - Országos Hematológiai és Infektológiai Intézet
Budapest, Hungary Recruiting
Show 6 more locations
-
Dél-budai Centrumkórház Szent Imre Egyetemi Oktatókórház
Budapest, Hungary Recruiting -
Észak-Pesti Centrumkórház - Honvédkórház
Budapest, Hungary Recruiting -
Clinical Centre, University of Debrecen
Debrecen, Hungary Recruiting -
Pécsi Tudományegyetem
Pécs, Hungary Recruiting -
Szegedi Tudományegyetem
Szeged, Hungary Recruiting -
Fejér Vármegyei Szent György Egyetemi Oktató Kórház
Székesfehérvár, Hungary Recruiting
Study contacts
- Principal investigator: Zoltan Pozsonyi, MD, PhD — Department of Internal Medicine and Hematology, Semmelweis University
- Study coordinator: Zoltan Pozsonyi, MD, PhD
- Email: pozsonyi.zoltan@semmelweis.hu
- Phone: +36208250944
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
SMS text check-ins to track symptoms for people with plasma cell disorders
This study tests whether daily SMS symptom prompts are feasible and acceptable for adults starting treatment for multiple myeloma or AL amyloidosis.
-
Acoramidis for ATTR-CM: Cardiac Imaging Study
This study tests whether acoramidis can improve heart structure and function in people with transthyretin amyloid cardiomyopathy.
-
Tec Dara for newly diagnosed multiple myeloma with light chain amyloidosis
This study tests whether tec listamab plus daratumumab can help newly diagnosed multiple myeloma with AL amyloidosis and whether the combination is safe.
-
How the IGLV1-44 light chain causes AL amyloidosis and POEMS
This project tests whether specific IGLV1-44 light‑chain sequences drive AL amyloidosis and POEMS and whether nanobodies can recognize and stabilize those light chains in adults with AL amyloidosis, POEMS, or multiple myeloma.
-
How N-glycosylation of light chains affects AL amyloidosis diagnosis and treatment
This project will test whether a sugar modification called N-glycosylation on immunoglobulin light chains helps cause disease or changes how AL amyloidosis and related monoclonal gammopathies behave in adults.
-
Cardiac MRI blood-flow imaging to distinguish types of hypertrophic cardiomyopathy
We will try cardiac MRI perfusion imaging to see if blood-flow patterns can distinguish people with different forms of hypertrophic cardiomyopathy, including genetic carriers and related conditions like Fabry disease and cardiac amyloidosis.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.